Reviva: Developing Next-Generation Therapies for Diseases with Significant Unmet Needs

Reviva Pharmaceuticals (Nasdaq: RVPH) is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023. Learn more at RVPHinfo.com.

Transcription:

A Phase 3 clinical-stage biopharma, Reviva Pharmaceuticals poised to disrupt markets worth billions - from schizophrenia to depression, ADHD, and beyond. With top-line data from a pivotal Phase 3 trial due in Q3 2023, the time to act is now. Learn more at RVPHinfo.com.